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ABSTRACT
Background. Complete ascertainment of the true rates of acute
kidney injury (AKI) and emerging trends are essential for plan-
ning of preventive strategies within health systems.
Methods. We conducted a retrospective cohort study from
2005 to 2014 using data from regional laboratory information
systems to determine incidence rates of AKI and severity Stages
1–3 in the Irish health system. Multivariable models were
developed to explore annual trends and the contributions of de-
mographic factors, clinical measures, geographic factors and lo-
cation of medical supervision expressed as adjusted odds ratios
(ORs) and 95% confidence intervals (CIs).
Results. From 2005 to 2014, incidence rates of AKI increased
from 6.1% (5.8–6.3) to 13.2% (12.7–13.8) per 100 patient-years
in men and from 5.0% (4.8–5.2) to 11.5% (11.0–12.0) in
women, P< 0.001. Stage 1 AKI accounted for the greatest
growth in incidence, from 4.4% (95% CI 4.3–4.6) in 2005 to
10.1% (95% CI 9.8–10.5) in 2014 (P< 0.001 for trend).
Compared with 2005, patients in 2014 were more likely to expe-
rience AKI [OR 4.53 (95% CI 4.02–5.1) for Stage 1, OR 5.22
(4.16–6.55) for Stage 2 and OR 4.11 (3.05–5.54) for Stage 3],
adjusting for changing demographic and clinical profiles.
Incidence rates of AKI increased in all locations of medical su-
pervision during the period of observation, but were greatest for
inpatient [OR 19.11 (95% CI 17.69–20.64)] and emergency
room settings [OR 5.97 (95% CI 5.56–6.42)] compared with a
general practice setting (referent).
Conclusion. Incidence rates of AKI have increased substantially
in the Irish health system, which were not accounted for by
changing demographic patterns, clinical profiles or location of
medical supervision.
Keywords: acute kidney injury, acute renal failure, AKI, epide-
miology, surveillance
INTRODUCTION
Acute kidney injury (AKI) is a global health issue, with severe
episodes contributing to high rates of adverse clinical and eco-
nomic outcomes [1–4]. The incidence of AKI varies widely in
reported studies, from 486 to 2147 per million per year, which
likely reflects differences in case ascertainment, changing defi-
nitions and the location of patient care [5–8]. The incidence of
hospital-acquired AKI is 5–10 times higher than that of
community-acquired cases [9]. AKI is a major independent
predictor of both short- and long-term mortality in multiple
settings and emerging evidence suggests that it also predicts
long-term risk for cardiovascular events and end-stage kidney
disease (ESKD) [4, 10–17].
Despite the public health importance of AKI, most published
studies to-date have focused primarily on dialysis-requiring
AKI (D-AKI) [18–20]. Evidence, mainly from the USA, has
shown that the incidence of D-AKI has increased significantly
in recent years, which may be related to the rising burden of
acute and chronic medical illness [18, 20]. Non-dialysis-requir-
ing AKI (ND-AKI) is a less well-studied entity and recent evi-
dence suggests that the magnitude of this condition is
substantially higher than D-AKI and may itself portend signifi-
cant health risks [21]. Although great strides have been made in
advancing the epidemiology of AKI, there remain several unan-
swered questions. First, there is residual doubt with regards to
data validity, as most published studies on annual trends have
relied mainly on clinical diagnosis codes rather than laboratory-
based criteria for the identification and tracking of AKI events
[22]. Second, clinical investigators have typically focused pri-
marily on the most severe form of AKI that necessitates dialysis,
with little or no data on less severe forms [23]. Third, there are
limited data on the burden of AKI within health systems and
the distribution of AKI events across the entire health system,
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especially in key locations where preventive efforts may confer
the greatest benefit [23].
To address these gaps in our knowledge, we determined tem-
poral trends in the incidence and severity of AKI among new
entrants to the Irish health system and further explored whether
any observed variation in incidence rates over time might be
explained by changes in demographic characteristics, markers of
health status or changes in baseline kidney function prior to AKI.
MATERIALS AND METHODS
Data source
We utilized data from the National Kidney Disease
Surveillance System, which serve to monitor trends and out-
comes of chronic kidney disease (CKD) and AKI in the Irish
health system [24]. Data sources included regional laboratory in-
formation systems, which capture all inpatient and outpatient
laboratory tests within a designated region, dialysis registers that
capture patients who progress to ESKD and mortality data files
from the national Central Statistics Office (CSO).
Cohort participants
We identified all patients with measured serum creatinine
values from two major health regions—Northwest region (from
2005 to 2014) and Midwest region (from 1999 to 2014)—and
linked laboratory data records over time using an expectation-
maximization (EM) algorithm-based probabilistic matching
strategy [25]. We selected participants with calibrated serum cre-
atinine measurements from 1 January 2005 to 31 December 2014.
Individuals with kidney failure receiving dialysis or who hadmiss-
ing data on age, sex and unmatched mortality records were ex-
cluded. Cohort participants who did not experience AKI were
included at the time of their first valid serum creatinine measure-
ment recorded in the health system. Cohort participants who ex-
perienced an AKI were included at the time of their first episode.
Outcome: AKI
The primary outcome of interest was the incidence of AKI
among new entrants into the health system. The Kidney Disease:
Improving Global Outcomes (KDIGO) criteria were used to
identify all AKI events from 2005 to 2014 and subclassify each
by severity grade [26]. The baseline serum creatinine was defined
as the median creatinine value recorded within 3 months prior
to the AKI event. Where creatinine values were unavailable prior
to an AKI episode, we improvized by using median creatinine
values recorded within 3 months following the AKI episode or
the minimum creatinine value within 48 h following an AKI
(Supplementary data, Figure S1). Per the KDIGO criteria, Stage
1 AKI was defined as an increase in creatinine by 50–100%
within 7 days or 26.5mmol/L above baseline within 48h, Stage
2 as an increase of 100–200% above baseline creatinine and
Stage 3 as a200% increase or an increase354mmol/L.
Primary exposure variable
The primary exposure variable was calendar year from 2005
to 2014.
Covariates
Baseline data on all participants were measured at the time of
study inclusion. Serum creatinine was measured using the modi-
fied kinetic Jaffe method and creatinine values were calibrated to
be traceable to an isotope dilution mass spectrometry (IDMS)
reference measurement procedure to ensure standardization.
Serum creatinine values were used to determine estimated glo-
merular filtration rate (eGFR; in mL/min/1.73 m2) for patients
using the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation and the Modification of Diet in Renal
Disease (MDRD) equation for sensitivity analysis [27, 28]. CKD
was defined according to the kidney disease dialysis quality out-
come initiative guidelines based on eGFR measurements [9].
Data were captured on an extensive list of laboratory measures
including indicators of inflammation [C-reactive protein, eryth-
rocyte sedimentation rate (ESR), white cell count and subtypes],
nutrition (serum albumin and total protein) and bone bio-
markers (serum calcium and phosphate). The location of medi-
cal supervision was defined as the location where the creatinine
test was ordered by the supervising physician and categorized as
inpatient facility (IP), outpatient facility (OP), general practice
(GP) and emergency room (ER). The identification of these loca-
tions was considered important to explore relationships between
the site of medical supervision and the frequency of AKI events.
The county of residence was extracted from the patient adminis-
tration system, which allowed us to classify patients by geogra-
phy. The principal counties served by the Northwest region of
Ireland included Donegal, Sligo and Leitrim while those served
by theMidwest region included Clare, Limerick and Tipperary.
Statistical analysis
Continuous variables are presented as mean6 standard de-
viation (SD) or median and interquartile range (IQR), as appro-
priate, while categorical variables are given as event numbers
with percentages. Group comparisons for continuous variables
were performed using the Kruskal–Wallis test while group
comparisons were performed with the chi-squared test.
Poisson regression utilizing robust standard error estimated
incident rates of AKI within the health system and rates were
expressed as events per 100 person-years for the entire cohort and
for selected subgroups across calendar years. Incidence rates of
AKI were compared across calendar years using the 2005year as
the referent with the generation of incidence rate ratios (IRRs).
Univariable and multivariable logistic regression models were de-
veloped to compare the likelihood of the first AKI across the years
2005–2014 with 2005 as the referent year. A purposeful selection
process was employed in model development. Associations were
expressed as odds ratios (ORs) and 95% confidence intervals (CIs);
a cut-off point of a¼ 0.05 was used to assess for statistical signifi-
cance. We assessed whether the likelihood of an AKI differed by
age, sex and eGFR across calendar years by including interaction
terms. All analyses were performed using R statistical software (R
Foundation for Statistical Computing, Vienna, Austria) [26].
Sensitivity analysis
Sensitivity analyses were conducted to evaluate the robust-
ness of our results. First, we restricted the definition of an AKI
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event to incorporate creatinine values recorded prior to a poten-
tial AKI episode to remove possible bias introduced by the in-
clusion of post-AKI creatinine concentrations. Second, we
examined to what extent AKI event rates and annual trends
were influenced by the definition of baseline creatinine concen-
tration prior to AKI. For this we substituted the median creati-
nine value with the mean creatinine concentration and repeated
the entire analysis. Finally, we determined whether our defini-
tion of eGFR altered observed trends by replacing the CKD-EPI
equation with the MDRD equation.
Ethics approval
The study was approved by the Ethics Committee at
University Hospital Limerick.
RESULTS
Baseline characteristics of the study cohort
The construction of the final study cohort from the Northwest
and Midwest regions of Ireland is shown in Figure 1. There were
40 786 (9%) laboratory-proven episodes of AKI among 451 646
patients from 2005 to 2014 (Table 1). Patients who experienced
an AKI episode were on average older and male, had higher se-
rum creatinine concentrations and lower eGFR values at baseline
(P< 0.001) and had significantly higher levels of inflammatory
markers and lower serum albumin levels. Most AKI episodes oc-
curred in patients who were hospitalized as IP. Among all AKI
episodes, Stage 1 occurred most frequently (81.3%), followed by
Stage 2 (11.6%) and Stage 3 (7.1%). Patients who sustained a
Stage 3 AKI event had baseline characteristics that reflected an
older and sicker cohort (Table 2).
Temporal trends in incidence rates of AKI
Incidence rates of AKI increased by at least 2-fold, from 5.48
in 2005 to 12.39 per 100 patient-years in 2014. For both men
and women, a trend of increasing incidence was observed be-
tween 2005 and 2014 (Figure 2a). Adjusting for age, sex
and location of supervision, incidence rates peaked in 2011
[IRR 2.07 (95% CI 1.81–2.38)] and plateaued thereafter
(Supplementary data, Table S1). Incidence rates were signifi-
cantly higher for men than for women [IRR 1.13 (95% CI 1.07–
1.18)] and increased significantly and substantially with ad-
vancing age. The adjusted IRR for patients>80 years of age was
>11-fold higher than for patients ages 18–39 years
(Supplementary data, Table S1). Within each age category, men
experienced significantly higher rates than women, and this
pattern persisted over time (Figure 2b). For men and women, a
relative plateauing of AKI rates was observed from 2010 to
2012, and this was most pronounced for patients in the age cat-
egories 60–79 and>80 years.
Temporal trends in incident rates by stage of AKI
Temporal trends in the incidence of AKI by severity stage are
presented in Table 3 and Figure 3. Overall, Stage 1 AKI accounted
for the greatest proportion of all AKI events. The pattern of an-
nual growth in incidence was similar for Stages 1 and 2 AKI, with
adjusted IRRs that increased significantly from 1.44 (95% CI
1.28–1.62) to 2.62 (2.32–2.96) and from 1.58 (95% CI 1.33–1.88)
to 2.83 (2.32–3.46), respectively (P< 0.001) (Supplementary
data, Table S2). In contrast, incidence rates of Stage 3 AKI in-
creased from 2006 until 2012 [peak IRR 2.27 (95% CI 2.01–2.57)]
and plateaued thereafter. Across all stages of AKI, rates were sig-
nificantly higher in men than in women and increased with ad-
vancing age.
AKI trends by location of supervision
Incidence rates of AKI increased significantly from 2005 to
2014 across all health care settings as shown in Table 3. Patients
classified as IP recorded the highest incidence rates of AKI com-
pared with patients observed in the ER, GP or OP settings.
With adjustment for age, sex and calendar year, IP had inci-
dence rates that were 15.5 times (13.66–17.63) greater than
those in the GP setting (Supplementary data, Table S1).
Factors associated with first AKI
The results of univariate and multivariable associations of first
AKI are shown in Table 4. In univariate analysis, the OR of AKI in-
creased in amonotonic fashion with each successive year.With ad-
justment for demographic characteristics, illness indicators, county
of residence and location of supervision, patients who entered the
health system in 2014 were significantly more likely to experience
an AKI compared with those in 2005 [OR 4.36 (95% CI 3.90–
4.87), P< 0.001]. To determine whether this relationship varied by
AKI stage, we repeated the analysis stratified by AKI stage in sepa-
rate logistic models. In each of these additional analyses the pattern
was similar with significantly higher ORs for AKI Stages 1–3 in
2014 compared with the referent 2005, as shown in Figure 4.
Increasing age [OR 1.25 (95% CI 1.24–1.26)] andmale gender [OR
1.28 (95% CI 1.22–1.35)] were significantly associated with AKI in-
cidence in themultivariable model. Compared with patients in GP,
patients managed as IP [OR 19.11 (95% CI 17.69–20.64)], attend-
ing the ER [OR 5.97 (95% CI 5.56–6.42)] or OP [OR 4.37 (95% CI
4.02–4.75)] were significantly more likely to experience an AKI
event. Incidence rates of AKI also varied significantly by county of
residence, which was not explained by patient-level factors or loca-
tion of medical supervision, as shown in Table 4. The final model
had excellent discrimination with a C-statistic of 0.93. Significant
interactions were observed between age and sex (P< 0.001) and
sex and calendar year (P< 0.001). Incorporating these interactions
in the model indicated that the likelihood of AKI was significantly
higher for men than for women in the earlier time periods but this
difference had almost disappeared in later years (Supplementary
data, Figure S2), particularly for those >50years of age
(Supplementary data, Figure S3).
SENSITIVITY ANALYSIS
We repeated the entire analysis, restricting the sample to
patients who had creatinine values recorded prior to the AKI
episode. This yielded a final cohort of 449 190 who experienced
30 836 (6.9%) AKI episodes and had similar demographic and
clinical characteristics to those of the original cohort. Similar to
before, we found that incidence rates increased with each suc-
cessive year and that the patterns of association mirrored those
of the primary analysis (Figure 5 and Supplementary data,
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Tables S3A and S3B). Similarly, substituting the mean for the
median serum creatinine in the assessment of baseline creati-
nine or using the MDRD equation instead of the CKD-EPI
equation in estimating baseline GFR, we found the same quali-
tative trends were observed and these are summarized in
Supplementary data, Tables S3–S5.
DISCUSSION
To our knowledge, this is the first study to describe annual
trends in the frequency of AKI by severity staging in the health
system and to characterize differences across major health care
settings. Using a laboratory-based definition of AKI, we demon-
strated a trend of increasing incidence of AKI over the past de-
cade, a pattern that was observed across all AKI Stages 1–3. The
rising trend was observed for both men and women and across
all age groups, although the greatest increases were observed in
elderly patients. Moreover, we identified the IP setting as the
most common location for AKI occurrence even though the
rates were also common in other key locations such as the ER
and OP settings. Several patient- and facility-levelcharacteristics
were associated with the occurrence of a first AKI event, includ-
ing older age, male gender, baseline kidney function, county of
residence and location of medical supervision, although these
did not sufficiently account for the rising annual trend in AKI
incidence.
We highlight a pattern of increasing incidence of AKI in
the Irish health system that was clearly manifested across
several locations of patient supervision. Increases in the ab-
solute rates of AKI were observed for men and women and
in all age groups, accounting for a more than 2-fold increase
in rates from 2005 to 2014. Given the mounting evidence
that connects AKI with substantial adverse impact on both
short- and long-term clinical outcomes [4, 10–17], it is im-
perative that we pay attention to these epidemiological
trends. A fundamental challenge in all health systems is
early detection of disease so that we can develop and imple-
ment effective prevention strategies [17, 29, 30]. In this
FIGURE 1: A Strengthening the Reporting of Observational Studies in Epidemiology flow diagram to illustrate cohort construction. The final
data set (n¼ 451 646) captured information on demographic characteristics, county of residence, primary location of patient supervision, labo-
ratory measures of health status, dialysis indicator variables and death.
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study we identified key clinical locations in the health sys-
tem where incidence rates of AKI were highest. By and large,
the IP setting was the most common site of AKI occurrence,
which is not surprising given that it accommodates the
sickest patients. Patients within the health system and need-
ing admission to an IP ward were almost 20-fold more likely
to develop an AKI. The pattern of annual incidence in-
creased to a peak in 2012 and appeared to plateau thereafter.
Table 1. Patient characteristics at baseline by the presence of AKI
Variable N No AKI AKI P-value
Patients, n (%) 451 646 410 860 (91) 40 786 (9)
Demographic characteristics
Age at baseline (years), mean (SD) 451 646 44.8 (17.5) 67.5 (18.1) <0.001
Age group categories (years), %
18–39 184 572 97.7 2.3
40–59 148 651 95.3 4.7
60–80 94 489 80.4 19.6
>80 23 934 53.9 46.1 <0.001
Gender, %
Women 241 696 91.7 8.3
Men 209 950 90.1 9.9 <0.001
Geographic factors, %
County of residence
Donegal 119 025 90.9 9.1
Sligo 56 521 91.2 8.8
Leitrim 26 154 91.6 8.4
Limerick 84 183 89.1 10.9
Clare 50 622 88.3 11.7
Tipperary 21 735 89.5 10.5
Other counties 27 551 94.5 5.5 <0.001
Hospital region
Midwest 208 879 89.9 10.1
Northwest 242 767 91.9 8.1 <0.001
Location of medical supervisiona
ER 87 193 85.7 14.3
GP 266 766 98.5 1.5
IP 46 584 61.6 38.4
OP 35 463 86.6 13.4 <0.001
Measures of kidney function
Serum creatinine (mmol/L), median (IQR) 451 646 75.0 (22.0) 81.0 (43.0) <0.001
eGFRb (mL/min/1.73 m2), median (IQR) 451 646 95.1 (32.2) 73.7 (44.5) <0.001
Plasma urea (mmol/L), median (IQR) 439 217 5.2 (2.2) 9.5 (8.6) <0.001
Baseline eGFR categoryc, %
 90 259 669 95.0 5.0
60–89 148 223 90.7 9.3
30–59 39 149 71.7 28.3
15–29 3702 39.1 60.9
<15 903 25.0 75.0 <0.001
Measures of inflammation
C-reactive protein (SI), median (IQR) 48 474 3.4 (8.8) 37.0 (102.0) <0.001
ESR, median (IQR) 141 905 9.5 (13.2) 32.0 (46.9) <0.001
White blood count, median (IQR) 416 369 7.3 (3.6) 10.4 (6.6) <0.001
Lymphocyte count, median (IQR) 401 969 1.9 (0.9) 1.3 (1.1) <0.001
Neutrophil count, median (IQR) 409 435 4.3 (2.9) 7.6 (6.4) <0.001
Measures of nutrition
Serum albumin (g/L), mean (SD) 282 547 39.2 (5.1) 30.8 (7.6) <0.001
Total protein (mmol/L), mean (SD) 255 996 68.4 (7.0) 61.1 (11.0) <0.001
Measures of bone metabolism
Serum calcium (mmol/L), mean (SD) 110 368 2.3 (0.1) 2.2 (0.2) <0.001
Serum phosphorus (mmol/L), mean (SD) 107 723 1.2 (0.3) 1.3 (0.5) <0.001
Other metabolic biomarkers
Serum potassium (mmol/L), mean (SD) 393 599 4.4 (0.5) 4.4 (0.8) <0.001
Serum uric acid (lmol/L), median (IQR) 46 992 308.0 (116.0) 347.7 (175.0) <0.001
Haemoglobin A1c (%), median (IQR) 31 590 5.7 (1.3) 6.6 (2.0) <0.001
Glucose (mmol/L), median (IQR) 103 517 5.0 (0.9) 6.2 (2.7) <0.001
Haemoglobin (g/dl), mean (SD) 420 580 14.0 (1.6) 12.4 (2.3) <0.001
aLocation of medical supervision refers to the location of the patient when the test was conducted.
beGFR was based on the CKD-EPI equation [19].
cExcluding patients who received dialysis at baseline.
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Our analysis would suggest that targeting of locations where
AKI is most likely to occur would be a primary goal.
Through early detection strategies including electronic alert
systems and adoption of early treatment interventions, it is
likely that many AKI events could be prevented and more
effectively managed [30]. Our analysis also suggests that
other locations should also be targeted, especially the ER
and outpatient clinics. These are critical points where
patients interact with their physicians and multidisciplinary
teams to management acute and chronic conditions.
Table 2. Patient characteristics at baseline by stage of AKI
Variable N Stage 1 Stage 2 Stage 3 P-value
Patients, n (%) 40 786 33 155 (81.3) 4734 (11.6) 2897 (7.1)
Age at baseline (years), mean (SD) 40 786 67.3 (18.3) 68.3 (17.5) 68.6 (16.7) 0.006
Age group categories (years), %
18–39 4300 85.4 9.7 4.9
40–59 6923 80.8 11.6 7.6
60–80 18 526 80.6 11.9 7.5
>80 11 037 81.1 11.9 7.0 <0.001
Gender, %
Women 19 965 80.8 12.4 6.7
Men 20 821 81.7 10.8 7.4 <0.001
County of residence, %
Donegal 10 806 80.7 11.9 7.4
Sligo 4970 80.3 12.8 6.9
Leitrim 2209 79.7 12.4 7.9
Limerick 9177 82.2 11.3 6.5
Clare 5930 81.5 11.6 6.9
Tipperary 2287 82.9 10.7 6.4
All other counties 1524 82.4 9.6 8.0 0.002
Hospital region, %
Midwest 21 155 82.0 11.1 6.9
Northwest 19 631 80.6 12.1 7.3 0.001
Location of medical supervisiona, %
ER 12 461 77.4 14.2 8.4
GP 4084 83.3 11.4 5.2
IP 17 897 83.7 10.0 6.3
OP 4746 80.6 10.6 8.8 <0.001
Laboratory variables
Measures of kidney function
Serum creatinine (lmol/L), median (IQR) 40 786 81.5 (42.0) 73.0 (34.0) 117.0 (222.0) <0.001
eGFR at baselineb (mL/min/1.73m2), median (IQR) 40 786 73.8 (44.1) 82.0 (37.4) 46.2 (68.3) <0.001
Urea (mmol/L), median (IQR) 39 641 8.7 (7.1) 12.2 (11.4) 23.8 (20.6) <0.001
Baseline eGFRc (mL/min/1.73 m2)
90 12 911 81.7 13.7 4.5
60–89 13 856 82.1 13.3 4.6
30–59 11 088 85.3 9.8 4.9
15–29 2254 75.8 1.3 22.8
<15 677 8.1 0.0 91.9 <0.001
Measures of inflammation
C-reactive protein (SI), median (IQR) 13 669 32.2 (93.0) 61.0 (134.2) 64.9 (147.0) <0.001
ESR, median (IQR) 24 209 30.0 (45.2) 37.0 (54.0) 44.8 (54.6) <0.001
White blood count, median (IQR) 40 272 10.2 (6.2) 11.7 (8.8) 11.4 (8.5) <0.001
Lymphocyte count, median (IQR) 39 273 1.3 (1.1) 1.1 (1.0) 1.0 (0.9) <0.001
Neutrophil count, median (IQR) 40 051 7.4 (6.0) 8.8 (8.2) 8.8 (7.9) <0.001
Measures of nutrition
Serum albumin (g/L), mean (SD) 36 359 31.3 (7.4) 29.1 (7.9) 28.4 (7.6) <0.001
Total protein (mmol/L), mean (SD) 32 969 61.4 (10.7) 59.9 (12.1) 59.7 (11.9) <0.001
Measures of bone metabolism
Serum calcium (mmol/L), mean (SD) 26 748 2.2 (0.2) 2.2 (0.2) 2.1 (0.3) <0.001
Serum phosphorus (mmol/L), mean (SD) 28 888 1.2 (0.4) 1.3 (0.5) 1.7 (0.8) <0.001
Metabolic biomarkers
Serum potassium (mmol/L), mean (SD) 40 472 4.3 (0.7) 4.4 (0.9) 4.7 (1.1) <0.001
Serum uric acid (umol/L), median (IQR) 8036 343.0 (169.3) 338.0 (184.2) 412.4 (211.2) <0.001
Haemoglobin A1c (%), median (IQR) 7538 6.6 (2.0) 6.7 (2.2) 6.5 (1.8) 0.007
Glucose (mmol/L), median (IQR) 13 590 6.2 (2.7) 6.3 (2.8) 6.3 (3.0) 0.367
Haemoglobin (g/dl), mean (SD) 39 854 12.5 (2.2) 12.4 (2.4) 11.8 (2.6) <0.001
aLocation of medical supervision refers to the location of the patient when the test was conducted.
beGFR was based on the CKD-EPI equation [19].
cExcluding patients who received dialysis at baseline.
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Our study has shed new light not only on the overall pattern
of AKI incidence over time but also on important trends
according to the severity of AKI. Of particular interest is the
finding that the greatest absolute increases in AKI incidence
were accounted for by increases in AKI Stage 1. From 2005 to
2014, absolute rates of AKI Stage 1 increased from 4.4 to 11.1%,
while the growth in Stage 2 (from 0.60 to 1.46%) and Stage 3
(from 0.46 to 0.81%) were less impressive. This would suggest
that greater should attention be given to these ‘minor’ AKI
events and their determinants. Equally important, the pattern
of AKI incidence differed by severity stage over time. Indeed,
on comparing IRR across calendar years, the IRR for Stage 3
FIGURE 2: (a) Temporal trends in the incidence of AKI by sex in the health system. (b) Temporal trends in the incidence of AKI by age and
sex in the health system. Dashed lines and error bars represent incidence rates with 95% CIs calculated from the direct method, whereas con-
tinuous lines and bands represent incident rates and 95% CIs calculated from Poisson regression.
FIGURE 3: (a) Temporal trends in the incidence rates of AKI by severity stage in the Irish health system. (b) Temporal trends in incidence
rates of Stage 2 and Stage 3 AKI (magnified).
Temporal trends of AKI in the health system 7
T
ab
le
3.
T
em
po
ra
lt
re
n
ds
in
in
ci
de
n
ce
ra
te
s
of
A
K
I
in
th
e
Ir
is
h
he
al
th
sy
st
em
fr
om
20
05
to
20
14
V
ar
ia
bl
ea
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
P
-v
al
ue
A
ll
pa
ti
en
ts
82
65
7
60
86
9
53
96
2
45
71
3
40
59
5
38
54
0
35
81
7
33
64
4
31
02
0
28
82
9
A
K
I
ev
en
ts
,n
45
29
41
89
43
57
41
08
40
39
40
23
40
91
40
25
38
54
35
71
A
ll
pa
ti
en
ts
5.
48
(5
.3
2–
5.
64
)
6.
88
(6
.6
8–
7.
08
)
8.
07
(7
.8
4–
8.
3)
8.
99
(8
.7
3–
9.
25
)
9.
95
(9
.6
6–
10
.2
4)
10
.4
4
(1
0.
13
–1
0.
75
)
11
.4
2
(1
1.
09
–1
1.
75
)
11
.9
6
(1
1.
61
–1
2.
31
)
12
.4
2
(1
2.
05
–1
2.
79
)
12
.3
9
(1
2.
01
–1
2.
77
)
<
0.
00
1
St
ag
e
1
4.
41
(4
.2
7–
4.
55
)
5.
58
(5
.4
0–
5.
76
)
6.
61
(6
.4
0–
6.
82
)
7.
25
(7
.0
1–
7.
49
)
8.
09
(7
.8
2–
8.
36
)
8.
58
(8
.3
0–
8.
86
)
9.
33
(9
.0
3–
9.
63
)
9.
68
(9
.3
6–
10
.0
0)
10
.0
5
(9
.7
2–
10
.3
8)
10
.1
1
(9
.7
6–
10
.4
6)
<
0.
00
1
St
ag
e
2
0.
60
(0
.5
5–
0.
65
)
0.
83
(0
.7
6–
0.
90
)
0.
92
(0
.8
4–
1.
00
)
1.
08
(0
.9
9–
1.
17
)
1.
15
(1
.0
5–
1.
25
)
1.
14
(1
.0
3–
1.
25
)
1.
29
(1
.1
7–
1.
41
)
1.
4
(1
.2
7–
1.
53
)
1.
52
(1
.3
8–
1.
66
)
1.
46
(1
.3
2–
1.
60
)
<
0.
00
1
St
ag
e
3
0.
46
(0
.4
1–
0.
51
)
0.
46
(0
.4
1–
0.
51
)
0.
54
(0
.4
8–
0.
60
)
0.
65
(0
.5
8–
0.
72
)
0.
70
(0
.6
2–
0.
78
)
0.
72
(0
.6
4–
0.
80
)
0.
80
(0
.7
1–
0.
89
)
0.
88
(0
.7
8–
0.
98
)
0.
85
(0
.7
5–
0.
95
)
0.
81
(0
.7
1–
0.
91
)
<
0.
00
1
M
en
6.
06
(5
.8
2–
6.
30
)
7.
67
(7
.3
6–
7.
98
)
9.
00
(8
.6
4–
9.
36
)
10
.7
7
(1
0.
33
–1
1.
21
)
10
.8
2
(1
0.
37
–1
1.
27
)
11
.4
7
(1
1.
00
–1
1.
94
)
12
.4
8
(1
1.
97
–1
2.
99
)
12
.0
2
(1
1.
54
–1
2.
5)
12
.3
7
(1
1.
86
–1
2.
88
)
13
.2
2
(1
2.
68
–1
3.
76
)
<
0.
00
1
St
ag
e
1
4.
91
(4
.6
9–
5.
13
)
6.
24
(5
.9
5–
6.
53
)
7.
48
(7
.1
5–
7.
81
)
8.
70
(8
.3
0–
9.
10
)
8.
75
(8
.3
4–
9.
16
)
9.
47
(9
.0
4–
9.
9)
10
.2
7
(9
.8
0–
10
.7
4)
9.
74
(9
.3
0–
10
.1
8)
10
.1
1
(9
.6
4–
10
.5
8)
10
.9
0
(1
0.
40
–1
1.
40
)
<
0.
00
1
St
ag
e
2
0.
62
(0
.5
4–
0.
70
)
0.
87
(0
.7
6–
0.
98
)
0.
94
(0
.8
2–
1.
06
)
1.
26
(1
.1
0–
1.
42
)
1.
21
(1
.0
5–
1.
37
)
1.
15
(0
.9
9–
1.
31
)
1.
35
(1
.1
7–
1.
53
)
1.
32
(1
.1
5–
1.
49
)
1.
34
(1
.1
6–
1.
52
)
1.
42
(1
.2
3–
1.
61
)
<
0.
00
1
St
ag
e
3
0.
53
(0
.4
6–
0.
60
)
0.
55
(0
.4
6–
0.
64
)
0.
58
(0
.4
9–
0.
67
)
0.
81
(0
.6
8–
0.
94
)
0.
86
(0
.7
3–
0.
99
)
0.
86
(0
.7
2–
1.
00
)
0.
86
(0
.7
2–
1.
00
)
0.
96
(0
.8
2–
1.
10
)
0.
91
(0
.7
6–
1.
06
)
0.
90
(0
.7
5–
1.
05
)
<
0.
00
1
W
om
en
5.
01
(4
.8
1–
5.
21
)
6.
24
(5
.9
8–
6.
50
)
7.
29
(6
.9
9–
7.
59
)
7.
66
(7
.3
4–
7.
98
)
9.
22
(8
.8
4–
9.
6)
9.
56
(9
.1
6–
9.
96
)
10
.5
3
(1
0.
10
–1
0.
96
)
11
.9
0
(1
1.
40
–1
2.
40
)
12
.4
8
(1
1.
95
–1
3.
01
)
11
.4
9
(1
0.
96
–1
2.
02
)
<
0.
00
1
St
ag
e
1
4.
01
(3
.8
3–
4.
19
)
5.
04
(4
.8
1–
5.
27
)
5.
88
(5
.6
1–
6.
15
)
6.
18
(5
.8
9–
6.
47
)
7.
54
(7
.1
9–
7.
89
)
7.
82
(7
.4
5–
8.
19
)
8.
54
(8
.1
5–
8.
93
)
9.
61
(9
.1
6–
10
.0
6)
9.
99
(9
.5
1–
10
.4
7)
9.
27
(8
.7
9–
9.
75
)
<
0.
00
1
St
ag
e
2
0.
59
(0
.5
2–
0.
66
)
0.
80
(0
.7
0–
0.
90
)
0.
91
(0
.8
0–
1.
02
)
0.
95
(0
.8
3–
1.
07
)
1.
11
(0
.9
7–
1.
25
)
1.
14
(1
.0
0–
1.
28
)
1.
23
(1
.0
8–
1.
38
)
1.
49
(1
.3
0–
1.
68
)
1.
71
(1
.5
0–
1.
92
)
1.
51
(1
.3
1–
1.
71
)
<
0.
00
1
St
ag
e
3
0.
41
(0
.3
5–
0.
47
)
0.
39
(0
.3
2–
0.
46
)
0.
51
(0
.4
3–
0.
59
)
0.
53
(0
.4
4–
0.
62
)
0.
58
(0
.4
8–
0.
68
)
0.
60
(0
.4
9–
0.
71
)
0.
76
(0
.6
4–
0.
88
)
0.
80
(0
.6
6–
0.
94
)
0.
78
(0
.6
4–
0.
92
)
0.
71
(0
.5
7–
0.
85
)
<
0.
00
1
A
ge
gr
ou
p
(y
ea
rs
)
18
–3
9
1.
55
(1
.4
0–
1.
70
)
1.
74
(1
.5
7–
1.
91
)
2.
18
(1
.9
9–
2.
37
)
2.
26
(2
.0
5–
2.
47
)
2.
53
(2
.3
0–
2.
76
)
2.
67
(2
.4
3–
2.
91
)
3.
00
(2
.7
4–
3.
26
)
2.
92
(2
.6
5–
3.
19
)
2.
95
(2
.6
7–
3.
23
)
2.
33
(2
.0
7–
2.
59
)
<
0.
00
1
40
–5
9
2.
50
(2
.3
2–
2.
68
)
3.
21
(2
.9
7–
3.
45
)
4.
24
(3
.9
5–
4.
53
)
4.
81
(4
.4
7–
5.
15
)
5.
09
(4
.7
1–
5.
47
)
5.
93
(5
.5
1–
6.
35
)
6.
43
(5
.9
7–
6.
89
)
6.
55
(6
.0
7–
7.
03
)
6.
84
(6
.3
2–
7.
36
)
7.
28
(6
.7
2–
7.
84
)
<
0.
00
1
60
–8
0
9.
53
(9
.1
4–
9.
92
)
14
.4
5
(1
3.
85
–1
5.
05
)
18
.2
3
(1
7.
5–
18
.9
6)
21
.2
5
(2
0.
40
–2
2.
10
)
23
.4
5
(2
2.
51
–2
4.
39
)
24
.5
6
(2
3.
57
–2
5.
55
)
27
.9
(2
6.
82
–2
8.
98
)
28
.5
9
(2
7.
49
–2
9.
69
)
29
.0
8
(2
7.
92
–3
0.
24
)
30
.1
6
(2
8.
95
–3
1.
37
)
<
0.
00
1
>
80
26
.1
9
(2
4.
95
–2
7.
43
)
38
.7
6
(3
7.
02
–4
0.
5)
43
.7
6
(4
1.
85
–4
5.
67
)
49
.4
9
(4
7.
38
–5
1.
6)
54
.8
8
(5
2.
72
–5
7.
04
)
55
.0
7
(5
2.
85
–5
7.
29
)
56
.4
4
(5
4.
18
–5
8.
7)
58
.1
4
(5
5.
86
–6
0.
42
)
57
.6
8
(5
5.
47
–5
9.
89
)
56
.8
8
(5
4.
56
–5
9.
20
)
<
0.
00
1
M
en
(y
ea
rs
)
18
–3
9
1.
72
(1
.4
8–
1.
96
)
1.
96
(1
.6
9–
2.
23
)
2.
60
(2
.2
9–
2.
91
)
2.
81
(2
.4
5–
3.
17
)
2.
76
(2
.4
0–
3.
12
)
2.
82
(2
.4
4–
3.
20
)
3.
41
(2
.9
9–
3.
83
)
3.
00
(2
.6
2–
3.
38
)
2.
94
(2
.5
4–
3.
34
)
2.
82
(2
.4
2–
3.
22
)
<
0.
00
1
40
–5
9
2.
83
(2
.5
5–
3.
11
)
3.
79
(3
.4
2–
4.
16
)
4.
63
(4
.1
9–
5.
07
)
5.
74
(5
.1
9–
6.
29
)
5.
41
(4
.8
5–
5.
97
)
6.
56
(5
.9
4–
7.
18
)
6.
94
(6
.2
6–
7.
62
)
6.
73
(6
.0
7–
7.
39
)
7.
04
(6
.3
2–
7.
76
)
7.
99
(7
.2
0–
8.
78
)
<
0.
00
1
60
–8
0
11
.2
0
(1
0.
58
–1
1.
82
)
16
.8
7
(1
5.
91
–1
7.
83
)
21
.1
1
(1
9.
97
–2
2.
25
)
25
.8
7
(2
4.
47
–2
7.
27
)
27
.0
1
(2
5.
55
–2
8.
47
)
28
.0
4
(2
6.
52
–2
9.
56
)
30
.6
4
(2
9.
02
–3
2.
26
)
28
.6
4
(2
7.
15
–3
0.
13
)
28
.6
7
(2
7.
10
–3
0.
24
)
31
.1
5
(2
9.
52
–3
2.
78
)
<
0.
00
1
>
80
27
.7
4
(2
5.
77
–2
9.
71
)
42
.0
4
(3
9.
31
–4
4.
77
)
48
.0
3
(4
5.
07
–5
0.
99
)
61
.1
1
(5
7.
79
–6
4.
43
)
59
.2
5
(5
5.
91
–6
2.
59
)
59
.6
8
(5
6.
32
–6
3.
04
)
61
.6
2
(5
8.
18
0–
65
.0
6)
57
.5
8
(5
4.
26
–6
0.
90
)
56
.6
6
(5
3.
44
–5
9.
88
)
58
.4
7
(5
5.
07
–6
1.
87
)
<
0.
00
1
W
om
en
(y
ea
rs
)
18
–3
9
1.
42
(1
.2
3–
1.
61
)
1.
57
(1
.3
5–
1.
79
)
1.
83
(1
.5
9–
2.
07
)
1.
88
(1
.6
3–
2.
13
)
2.
34
(2
.0
4–
2.
64
)
2.
55
(2
.2
3–
2.
87
)
2.
67
(2
.3
4–
3.
00
)
2.
85
(2
.4
8–
3.
22
)
2.
97
(2
.5
8–
3.
36
)
1.
86
(1
.5
4–
2.
18
)
<
0.
00
1
40
–5
9
2.
22
(1
.9
9–
2.
45
)
2.
71
(2
.4
1–
3.
01
)
3.
89
(3
.5
1–
4.
27
)
4.
03
(3
.6
0–
4.
46
)
4.
80
(4
.2
9–
5.
31
)
5.
31
(4
.7
5–
5.
87
)
5.
96
(5
.3
5–
6.
57
)
6.
35
(5
.6
5–
7.
05
)
6.
61
(5
.8
5–
7.
37
)
6.
40
(5
.6
1–
7.
19
)
<
0.
00
1
60
–8
0
8.
16
(7
.6
8–
8.
64
)
12
.5
3
(1
1.
78
–1
3.
28
)
15
.7
9
(1
4.
85
–1
6.
73
)
17
.8
1
(1
6.
75
–1
8.
87
)
20
.4
3
(1
9.
21
–2
1.
65
)
21
.5
6
(2
0.
26
–2
2.
86
)
25
.4
4
(2
4–
26
.8
8)
28
.5
4
(2
6.
92
–3
0.
16
)
29
.5
6
(2
7.
84
–3
1.
28
)
28
.9
1
(2
7.
11
–3
0.
71
)
<
0.
00
1
>
80
25
.1
1
(2
3.
52
–2
6.
70
)
36
.4
4
(3
4.
20
–3
8.
68
)
40
.6
9
(3
8.
22
–4
3.
16
)
42
.2
7
(3
9.
62
–4
4.
92
)
51
.8
7
(4
9.
05
–5
4.
69
)
51
.6
7
(4
8.
73
–5
4.
61
)
52
.8
(4
9.
83
–5
5.
77
)
58
.6
4
(5
5.
52
–6
1.
76
)
58
.5
9
(5
5.
57
–6
1.
61
)
55
.5
3
(5
2.
37
–5
8.
69
)
<
0.
00
1
Lo
ca
ti
on
of
m
ed
ic
al
su
pe
rv
is
io
nb
G
P
0.
71
(0
.6
4–
0.
78
)
1.
04
(0
.9
4–
1.
14
)
1.
38
(1
.2
5–
1.
51
)
1.
33
(1
.1
9–
1.
47
)
1.
64
(1
.4
8–
1.
80
)
1.
74
(1
.5
7–
1.
91
)
2.
20
(2
.0
0–
2.
40
)
2.
28
(2
.0
7–
2.
49
)
2.
72
(2
.4
8–
2.
96
)
2.
36
(2
.1
3–
2.
59
)
<
0.
00
1
E
R
8.
21
(7
.7
5–
8.
67
)
10
.8
5
(1
0.
26
–1
1.
44
)
12
.2
5
(1
1.
6–
12
.9
)
13
.8
4
(1
3.
1–
14
.5
8)
15
.0
1
(1
4.
23
–1
5.
79
)
15
.6
0
(1
4.
79
–1
6.
41
)
17
.7
7
(1
6.
9–
18
.6
4)
18
.7
3
(1
7.
84
–1
9.
62
)
18
.8
2
(1
7.
91
–1
9.
73
)
19
.7
9
(1
8.
85
–2
0.
73
)
<
0.
00
1
IP
28
.7
6
(2
7.
80
–2
9.
72
)
32
.8
5
(3
1.
71
–3
3.
99
)
34
.3
(3
3.
13
–3
5.
47
)
39
.5
8
(3
8.
21
–4
0.
95
)
40
.7
8
(3
9.
31
–4
2.
25
)
44
.6
4
(4
3.
09
–4
6.
19
)
46
.2
8
(4
4.
64
–4
7.
92
)
49
.3
0
(4
7.
57
–5
1.
03
)
46
.4
4
(4
4.
57
–4
8.
31
)
46
.1
7
(4
4.
24
–4
8.
10
)
<
0.
00
1
O
P
6.
46
(5
.8
4–
7.
08
)
7.
54
(6
.7
3–
8.
35
)
10
.3
2
(9
.3
1–
11
.3
3)
14
.0
5
(1
2.
93
–1
5.
17
)
17
.3
(1
6.
04
–1
8.
56
)
18
.3
7
(1
7.
04
–1
9.
70
)
17
.4
4
(1
6.
16
–1
8.
72
)
16
.6
2
(1
5.
27
–1
7.
97
)
16
.8
3
(1
5.
42
–1
8.
24
)
17
.7
3
(1
6.
25
–1
9.
21
)
<
0.
00
1
H
os
pi
ta
lr
eg
io
n
N
or
th
w
es
t
re
gi
on
4.
18
(4
.0
2–
4.
34
)
6.
14
(5
.8
9–
6.
39
)
7.
47
(7
.1
6–
7.
78
)
8.
14
(7
.7
9–
8.
49
)
9.
77
(9
.3
6–
10
.1
8)
9.
51
(9
.0
8–
9.
94
)
10
.9
4
(1
0.
47
–1
1.
41
)
11
.7
1
(1
1.
22
–1
2.
2)
12
.7
9
(1
2.
24
–1
3.
34
)
13
.7
3
(1
3.
14
–1
4.
32
)
<
0.
00
1
M
id
w
es
t
re
gi
on
8.
30
(7
.9
7–
8.
63
)
7.
97
(7
.6
3–
8.
31
)
8.
74
(8
.3
9–
9.
09
)
9.
85
(9
.4
6–
10
.2
4)
10
.1
2
(9
.7
1–
10
.5
3)
11
.2
5
(1
0.
82
–1
1.
68
)
11
.8
7
(1
1.
41
–1
2.
33
)
12
.2
0
(1
1.
71
–1
2.
69
)
12
.1
1
(1
1.
62
–1
2.
60
)
11
.2
8
(1
0.
79
–1
1.
77
)
<
0.
00
1
C
ou
nt
y
of
re
si
de
nc
e
D
on
eg
al
4.
80
(4
.5
5–
5.
05
)
7.
15
(6
.7
7–
7.
53
)
8.
39
(7
.9
3–
8.
85
)
9.
10
(8
.5
8–
9.
62
)
10
.9
8
(1
0.
36
–1
1.
6)
10
.9
3
(1
0.
28
–1
1.
58
)
11
.5
5
(1
0.
88
–1
2.
22
)
13
.5
5
(1
2.
80
–1
4.
30
)
13
.1
7
(1
2.
39
–1
3.
95
)
14
.6
8
(1
3.
82
–1
5.
54
)
<
0.
00
1
Sl
ig
o
3.
97
(3
.6
7–
4.
27
)
6.
25
(5
.7
6–
6.
74
)
8.
38
(7
.7
1–
9.
05
)
9.
19
(8
.4
–9
.9
8)
11
.0
5
(1
0.
11
–1
1.
99
)
10
.9
1
(9
.9
1–
11
.9
1)
14
.2
6
(1
3.
09
–1
5.
43
)
13
.8
3
(1
2.
61
–1
5.
05
)
17
.5
6
(1
6.
14
–1
8.
98
)
18
.2
4
(1
6.
75
–1
9.
73
)
<
0.
00
1
Li
m
er
ic
k
8.
97
(8
.4
2–
9.
52
)
8.
61
(8
.0
4–
9.
18
)
9.
02
(8
.4
7–
9.
57
)
10
.7
4
(1
0.
11
–1
1.
37
)
10
.5
4
(9
.8
9–
11
.1
9)
11
.5
5
(1
0.
87
–1
2.
23
)
12
.6
9
(1
1.
94
–1
3.
44
)
13
.5
7
(1
2.
78
–1
4.
36
)
13
.2
0
(1
2.
39
–1
4.
01
)
12
.7
8
(1
1.
96
–1
3.
60
)
<
0.
00
1
Le
it
ri
m
3.
83
(3
.3
6–
4.
30
)
6.
10
(5
.3
5–
6.
85
)
6.
84
(5
.9
5–
7.
73
)
8.
98
(7
.8
6–
10
.1
0)
12
.0
0
(1
0.
60
–1
3.
40
)
9.
62
(8
.3
3–
10
.9
1)
13
.3
8
(1
1.
80
–1
4.
96
)
11
.1
9
(9
.7
5–
12
.6
3)
14
.4
5
(1
2.
63
–1
6.
27
)
16
.2
1
(1
4.
18
–1
8.
24
)
<
0.
00
1
C
la
re
8.
13
(7
.4
9–
8.
77
)
8.
02
(7
.3
7–
8.
67
)
9.
46
(8
.7
5–
10
.1
7)
11
.8
3
(1
0.
97
–1
2.
69
)
11
.8
4
(1
0.
94
–1
2.
74
)
14
.2
9
(1
3.
3–
15
.2
8)
15
.3
1
(1
4.
23
–1
6.
39
)
15
.2
2
(1
4.
09
–1
6.
35
)
16
.1
1
(1
4.
94
–1
7.
28
)
13
.2
1
(1
2.
08
–1
4.
34
)
<
0.
00
1
T
ip
pe
ra
ry
10
.3
9
(9
.2
5–
11
.5
3)
9.
07
(7
.9
9–
10
.1
5)
10
.0
3
(8
.8
9–
11
.1
7)
8.
72
(7
.6
0–
9.
84
)
11
.4
4
(1
0.
08
–1
2.
80
)
11
.7
(1
0.
33
–1
3.
07
)
11
.2
1
(9
.8
1–
12
.6
1)
10
.4
3
(8
.9
9–
11
.8
7)
12
.2
0
(1
0.
64
–1
3.
76
)
11
.5
4
(9
.9
5–
13
.1
3)
0.
00
1
A
ll
ot
he
r
co
un
ti
es
3.
68
(3
.1
0–
4.
26
)
4.
96
(4
.2
0–
5.
72
)
5.
42
(4
.5
9–
6.
25
)
5.
07
(4
.2
4–
5.
90
)
6.
04
(5
.0
7–
7.
01
)
6.
19
(5
.2
4–
7.
14
)
5.
73
(4
.8
2–
6.
64
)
5.
82
(4
.9
2–
6.
72
)
6.
65
(5
.6
7–
7.
63
)
7.
29
(6
.2
3–
8.
35
)
<
0.
00
1
a I
nc
id
en
ce
ra
te
s
ex
pr
es
se
d
at
ev
en
ts
pe
r
10
0
pa
ti
en
ts
at
ri
sk
w
it
h
95
%
C
Is
.
b
Lo
ca
ti
on
of
m
ed
ic
al
su
pe
rv
is
io
n
re
fe
rs
to
th
e
lo
ca
ti
on
of
th
e
pa
ti
en
t
w
he
n
th
e
te
st
w
as
co
nd
uc
te
d.
8 A.G. Stack et al.D
AKI appears to peak in 2012 at 2.27 (95% CI 2.01–2.57) and de-
clined thereafter to 2.03 (95% CI 1.75–2.36) compared with
AKI Stages 1 and 2. This might suggest that the driving forces
for Stage 3 AKI are better managed, including earlier recogni-
tion and management of AKI Stages 1 and 2 and thereby less
transition to Stage 3.
Our study has several strengths that merit comment. Our
analysis depended solely on a laboratory-based approach. The
measurement of serum creatinine was based on assays that are
traceable to IDMS. The diagnosis of AKI using KDIGO criteria
was determined based solely on serum creatinine concentra-
tions from regional laboratory systems, thereby avoiding the
FIGURE 4: Adjusted OR for the first AKI event by the stage of AKI across calendar years in the Irish health system. The relationship between
calendar year and the OR of AKI is modelled separately for AKI Stages 1–3 with year 2005 as the referent. In each model, covariates for adjust-
ment include age, sex, baseline GFR estimated using the CKD-EPI equation, county of residence, location of medical supervision, laboratory
measures of illness (haemoglobin, serum albumin, white blood cell count, serum potassium, serum calcium and serum phosphorus concentra-
tion) and calendar year. P< 0.001 for each year compared with referent 2005.
Table 4. Factors associated with the first AKI in the Irish health system
Variable Unadjusted OR (95% CI) P-value Adjusted OR (95% CI)a P-value
Age (per 5 years) 1.41 (1.40–1.41) <0.001 1.25 (1.24–1.26) <0.001
Men (versus women) 1.22 (1.20–1.25) <0.001 1.28 (1.22–1.35) <0.001
Baseline eGFRb (per 5 unit decrease) 1.17 (1.17–1.17 <0.001 1.01 (1.01–1.02) <0.001
County of residence
Donegal (reference) 1.00 – 1.00 –
Sligo 0.97 (0.93–1.00) 0.050 1.09 (1.00–1.18) 0.040
Leitrim 0.92 (0.88–0.97) <0.001 0.88 (0.79–0.98) 0.020
Limerick 1.23 (1.19–1.26) <0.001 1.70 (1.60–1.81) <0.001
Clare 1.33 (1.28–1.37) <0.001 1.91 (1.74–2.08) <0.001
Tipperary 1.18 (1.12–1.24) <0.001 0.89 (0.78–1.01) 0.080
All other counties 0.59 (0.55–0.62) <0.001 0.34 (0.31–0.38) <0.001
Location of medical supervisionc
GP (reference) 1.00 – 1.00 –
ER 10.72 (10.34–11.12) <0.001 5.97 (5.56–6.42) <0.001
IP 40.13 (38.70–41.60) <0.001 19.11 (17.69–20.64) <0.001
OP 9.94 (9.52–10.38) <0.001 4.37 (4.02–4.75) <0.001
Calendar year
2005 (reference) 1.00 – 1.00 –
2006 1.27 (1.22–1.33) <0.001 1.65 (1.49–1.83) <0.001
2007 1.52 (1.45–1.58) <0.001 1.93 (1.74–2.13) <0.001
2008 1.70 (1.63–1.78) <0.001 2.66 (2.40–2.95) <0.001
2009 1.91 (1.82–1.99) <0.001 2.81 (2.54–3.11) <0.001
2010 2.01 (1.92–2.10) <0.001 3.09 (2.78–3.42) <0.001
2011 2.22 (2.13–2.33) <0.001 3.70 (3.33–4.10) <0.001
2012 2.34 (2.24–2.45) <0.001 4.05 (3.64–4.50) <0.001
2013 2.45 (2.34–2.56) <0.001 4.09 (3.67–4.56) <0.001
2014 2.44 (2.33–2.55) <0.001 4.36 (3.90–4.87) <0.001
aMultivariable models show adjusted ORs and corresponding 95% CIs. Model is adjusted for the following measures assessed at baseline: age, sex, baseline GFR estimated using CKD-
EPI equation, county of residence, location of medical supervision, laboratory measures of illness (haemoglobin, serum albumin, white blood cell count, serum potassium and serum
urea concentration) and calendar year; C-statistic ¼ 0.95.
beGFR was based on the CKD-EPI equation [19].
cLocation of medical supervision refers to the location of the patient when the laboratory test was conducted.
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need for hospital-based coding. Therefore our analysis provides
a more accurate reflection of the true event rate of AKI in the
health system [22]. An equally important advantage of our
study was the availability of serum creatinine measurements
measured prior to the AKI event in 87% of all patients.
Accordingly we were able to ascertain the baseline stage of
CKD and baseline creatinine to define the presence and severity
of AKI. Finally, our study was strengthened by the use of large
regional samples that included 451 646 patients with extensive
demographic, laboratory and facility-level data captured over
time. Despite these strengths, some weaknesses were apparent.
First, we did not have available data on comorbidity and medi-
cal procedures, and therefore adjustment for case mix depended
on laboratory parameters to reflect the presence and severity of
illness. Nevertheless, the final set of demographic characteristics
and clinical and geographic variables included in our model
were important enough to yield a C-statistic of 0.93. Second,
our analysis lacked data on hospital admission and length of
stay, information that would have further clarified our under-
standing of community and hospital-based AKI events. Instead,
we were able to pinpoint with certainty the exact location of
medical supervision from blood request forms completed by
the supervisory physicians. Third, it is possible that underre-
porting of Stage 3 AKI events may have occurred, as our analy-
sis did not capture acute dialysis-requiring AKI. Similarly,
underreporting of Stages 2 and 3 events may have resulted from
our dependence on creatinine values near the initiation of an
AKI episode rather than on maximal values. Fourth, longitudi-
nal tracking of patients in the Irish health system was based on
a probabilistic matching strategy rather than a unique identifier
[25]. Finally, we readily acknowledge the limitations of serum
creatinine as a diagnostic marker of AKI, as it has been shown
to be affected by factors independent of GFR such age, sex, race,
body size, diet and certain drugs [31].
Within the Irish health system, we demonstrate patterns
of increasing incidence of AKI from 2005 to 2014. For men
and women from all age groups, incident rates of AKI in-
creased over time. Increasing incidence was observed for all
stages of AKI, but most of the increase was accounted for by
accelerated growth of Stage 1 AKI. AKI events were more
common in the key areas of medical supervision and physical
locations that could potentially be targeted for early detection
and prevention programmes. Changes in patient- and
facility-level characteristics were significantly associated with
an increasing incidence of AKI, however, adjustment for
these did not fully account for the observed growth. Effective
management of AKI in health systems requires robust sur-
veillance systems embedded within the health system to track
the frequency and impact of AKI events over time as well as
monitor the effectiveness of preventive strategies in high-risk
clinical settings. The goal of the National Kidney Disease
Surveillance System in Ireland is to better understand the
evolving landscape of AKI in the Irish health system, its
determinants and outcomes, resource utilization and costs in
order to improve both patient outcomes and health system
performance.
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